



Institutional Biosafety Committee
Meeting Minutes

The meeting was called to order on 9/23/2025 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance

Voting Members Present:

Dafang Wang
Hwan Kim
Rachel Brownlee
Jorge Escobar
Nicholas Carpino
Jeronimo Cello
Christopher Kuhlrow
Kimberly Bowe

Non-Voting Attendees, Staff and Guests Present:

Rebecca Dahl
Terrance Roush
Aimee Minton

Recording:

Erin Augello

ITEMS

1. Meeting called to order at 11:30AM

2. Next Meeting Date and General Announcements

The next meeting date is 10/28/2025. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of Minutes from Last Meeting

Review type: Full Committee Review

Action: Approved

Effective date: 9/23/2025

Vote: Total = 8 for = 8 Opposed = 0 Abstained = 0

4. Report on continuing reviews requiring IBC review

This section was reviewed and noted by the committee.

5. Report on New Studies for Committee Review

a. PROTO202500027 Repair of DNA damage in human cells

PI:	Peng Mao
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	National Cancer Institute
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-1

Determination: Modifications Required

Modifications (If Applicable):

- i. In Section: Protocol Team Members
Item 1. Complete table by indicating whether each team member is involved with the procedures, in the column "Involved with Procedures".
- ii. In Section: Funding Sources
Item 1. Please provide Grants Office ID number.
- iii. In Section: Bacteria, Yeasts, Fungi, or Parasites
Item 1. All bacteria and yeasts are "BSL-1"
- iv. In Section: Biohazards
Item 1. All bacteria and yeasts are "BSL-1"
- v. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. Please include NIH Section.
In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 1. Description of recombinant nucleic acid work is insufficient; please expand with details.
Item 6. Please remove "such as" in the Microbes section. If there are additional E. coli strains other than DH5a and BL21 please indicate where appropriate, including on the Bacteria, Yeasts, Fungi, or Parasites page.
- vi. In Section: Risk Group and Containment Practices
Item 1. RG is missing. Please indicate RG3.
- vii. In Section: Exposure Assessment and Protective Equipment
Item 1. The description provided is not relevant to infectious agents. Please revise to address the actual consequences of exposure, specifically: (1) the low but real possibility of exposure to replication-competent lentivirus (RCL) even with third-

generation vectors, (2) the potential for insertional mutagenesis from lentiviral integration, and (3) the consequences of possible exposure to bloodborne pathogens from human cell lines.

Item 4. Please provide information for BSC, including location and date of last certification.

viii. In Section: Waste Management

Item 1. 1. Usual concentration for bleach is 10% but at least 1% is required in most cases. Include the amount of time the disinfectant has to sit on the contaminated area before it is disinfected. Waste disposal and autoclave location are missing.

ix. In Section: Protocol Team Members

Item 1. Please check "Yes" for all lab staff that are involved with procedures.

x. In Section: Funding resources

Item 1. Please provide requested information.

xi. In Section: Recombinant or Synthetic Nucleic Acid Work Description

Item 1. A brief description of the rsNAM work is all that is required here. Please Condense the response by removing procedural details (e.g., reagents, centrifugation steps, etc.), and instead clearly state what recombinant or synthetic nucleic acids are used, what host/vector systems are involved, and whether any genes are introduced.

xii. In Section: Risk Group and Containment Practices

Item 2. Physical containment for NIH Guidelines does not need to be BSL-2. Please indicate BSL-1.

xiii. Exposure Assessment and Protective Equipment

Although *Saccharomyces cerevisiae* is unlikely to cause disease in healthy human Adults it is considered to be an opportunistic pathogen and can in rare cases cause serious infections in immunocompromised individuals. Please acknowledge potential risks involved with working with *S. cerevisiae*, particularly in individuals with severe immunosuppression, prolonged antibiotic therapy, or other compromising factors.

Effective Date: 9/25/2025

Project Expiration: 9/24/2026

Votes:

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

b. Review of PROTO202500028 HIV associated pain and OIH

PI:	Shao Jun Tang
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	National Institutes of Health, Grant Office ID: , Funding Source ID: R01DA062257 • Name: National Institutes of Health, Grant Office ID: , Funding Source ID: R01DA050530

	• Name: National Institutes of Health, Grant Office ID: , Funding Source ID: R01DA057195 • Name: National Institutes of Health, Grant Office ID: , Funding Source ID: R01NS079166
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-1

Determination: Modifications Required

Modifications (If Applicable):

- i. In Section: Rodent Gene Transfer: Virus
Item 2. AAV is infectious. Therefore, check "Yes".
- ii. In Section: Exposure Assessment and Protective Equipment
Item 4. Exposure to AAV has the very minimal chance of leading to insertional mutagenesis.

Effective Date: 9/25/2025

Project Expiration: 9/24/2026

Votes:

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

c. Review of PROTO202500030 TET1 in liver diseases

PI:	Chiung-Kuei Huang
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	National Institutes of Health
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

- i. In Section: Protocol team members
Item 1. PI should indicate whether he will be involved or not with the procedures.
- ii. In Section: Tissues, Blood, or Body Fluids
Item 1. Human cell lines/tissue are BSL-2.
- iii. In Section: Primary Cells or Cell Lines
Item 1. Human cell lines are BSL-2.

iv. In Section: Biohazards

Item 1. Human cell lines/tissue are BSL-2.

v. In Section: Recombinant or Synthetic Nucleic Acid Work Description

Item 1. Description of recombinant nucleic acid work is insufficient; please expand with details.

Item 7. PI indicates using AAV here and in #13, but does not mention it in previous sections. Please clarify. It seems that AAV vector is going to be used. If an AAV vector is going to be used, PI should list in on the Viruses or Prions and Biohazards pages.

Item 10. The description “Amphitropic for Non-Rodent Mammalian Cells” is inaccurate for lentiviral vectors. PI should clarify which envelope protein is used (e.g., VSV-G) and state the correct tropism. Note that VSV-G pseudo typed lentivirus has broad mammalian tropism, including rodent and non-rodent cells.

vi. In Section: Rodent Gene Transfer: Virus

Item 2. "Yes" should be checked here. The vectors used (lentivirus and AAV) are infectious, as these particles can transduce cells even if they cannot propagate further.

Item 3. PI indicates use of helper virus here but not in Item #9 of rsNAM Work Description page. Please clarify.

vii. In Section: Risk Group and Containment Practices

Item 2. Please indicate ‘BSL-2’ in the section ‘NIH Guidelines’, not BL-1.

viii. In Section: Exposure Assessment and Protective Equipment

Item 1. Please include information related to possible consequences of exposure to viruses and potential bloodborne pathogens. Not asking of the level of risk here.

The statement “The lentivirus requires polybrene to infect human cells” is misleading.

The virus is infectious on its own; polybrene simply improves the efficiency in some cell types. For second- or third-generation lentiviral vectors (HIV-derived), there is a low but real probability of generating replication-competent lentivirus (RCL) and the consequences of exposure to this RCL should be discussed here. In addition, all lentiviral vectors integrate into the host genome and carry a risk of insertional mutagenesis. AAV vectors (replication-defective) are generally non-pathogenic; however, AAV vectors can integrate at low frequency and also pose a risk of insertional mutagenesis. Please indicate. Finally, human cell lines are being handled which may harbor latent or undetected bloodborne pathogens. PI should briefly describe the possible consequences of exposure to these infectious agents.

Item 4. The BSC on record is A2 not A1. Please correct.

ix. In Section: Dual Use of Research of Concern

Item 2. There is no dual use research of concern (DURC) in this protocol; therefore, the information provided in this section should be removed.

x. In Section: Waste Management

Item 1. Here, please indicate concentration of bleach is to be used.

Item 3. Please include information related to how and where decontaminated material will be disposed of in the event of a biological accident.

Item 4. Please include sharp waste in the waste disposal

Effective Date: 9/25/2025

Project Expiration: 9/24/2026

Votes:

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

d. Review of PROTO202500032 Synthetic multicellularity

PI:	David Glass
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	• Name: Stony Brook University
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIIF
Containment Conditions:	BSL-3

Determination: Modifications required**Modifications (If Applicable):**

- i. In Section: Funding resources
Item 1. Please provide requested information in Table.
- ii. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. Sections III-A, III-B, and III-D are not appropriate here, please remove and choose Section III-F. Only 3F applies.
- iii. In Section: Exposure Assessment and Protective Equipment
Item 1. PI indicates potential consequences expected from exposure to K12 E.Coli strain. Please describe.
- iv. In Section: Waste Management
Items 1&3. Include incubation time with disinfectant.

Effective Date: 9/25/2025**Project Expiration:** 9/24/2026**Votes:**

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

6. Report on Amendments Requiring Full IBC Review

a. Review of AMEND202500060 Nitric oxide signaling in bacteria

PI:	Elizabeth Boon
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None

Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. In Section: Bacteria, Yeasts, Fungi, or Parasites
Item 1. It seems that *Shewanella oneidensis*, *Shewanella woodyi*, *Pseudoalteromonas atlantica*, and *Vibrio harveyi* are going to be used to obtain DNA for further cloning experiment. If they will be cultured in the lab, please list in the 'Bacteria, Yeast, Fungi or Parasites' AND 'Biohazards' sections.
- ii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 1. NOTE: The various bacteria being used are designated by Risk Groups not BSLs. BSLs are the containment level used for a particular Risk Group. Please change wording to reflect the correct designation for each species. Further, the description "DNA comes from various BSL-1 bacteria such as *Shewanella oneidensis*, *Shewanella woodyi*, *Pseudoalteromonas atlantica*, and *Vibrio harveyi*" is vague. The phrase "such as" suggests that additional organisms beyond those listed may be used. Please provide a complete list of all bacterial sources to be used, rather than examples, so the scope of the work is clear.
Item 2. The statement "We clone H-NOX and NosP proteins (NO-sensing domains) as well as associated enzymes such as diguanylate cyclases and histidine kinases" is vague. The phrase "such as" suggests that additional proteins or enzymes beyond those listed may be used. Please provide a complete and specific list of all proteins/enzymes intended for cloning, rather than examples, to clearly define the scope of the work.
Items 3, 6 (Microbes) and 7. Similar comments to those described in 1 and 2 apply to the wording in these items.
- iii. In Section: Exposure Assessment and Protective Equipment
Item 1. Please describe consequences of exposure to all bacteria that will be used in this protocol. "BSL-2" does not answer the question.
- iv. In Section: Waste Management
Item 2. Provide location of autoclave.
Item 3. Please indicate amount of time disinfectant will be applied for decontamination in the event of a biological accident.

Effective Date: 8/1/2025**Project Expiration:** 7/31/2026**Votes:**

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

b. Review of AMEND202500077 Modification

PI:	Todd Miller
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. In Section: Primary Cells or Cell Lines
Item 1. MCF10A cells are mentioned as being used in this protocol in the Waste Section. They are not described here. Please include requested information in table.
- ii. In Section: Biohazards
Item 1. If MCF10A cells are to be used, please add them to Table.
- iii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 14. Check "Yes" due to use of baculovirus.

Effective Date: 9/22/2025**Project Expiration:** 9/21/2026**Votes:**

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

c. Review of AMEND202500086 Adding new personnel to protocol 628253

PI:	Bettina Fries
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. In Section: Biosafety Summary

Item 1. Select rsNAM from the dropdown menu and provide the requested information in appropriate subsequent sections, including 'Recombinant or Synthetic Nucleic Acid Usage' and 'Recombinant or Synthetic Nucleic Acid Work Description.' Additionally, select 'Bacteria Yeast, Fungi, or Parasites' from the dropdown menu and provide the requested information, including in the 'Biohazards' section.

ii. In Section: Exposure Assessment and Protective Equipment

Item 4. There are two rooms that are identified as 15-060, 060L and 060F. PI should specify exactly which room contains the BSC to be utilized.

iii. In Section: Waste Management

Item 1. What is the rationale for utilizing 40% bleach? Is 10% bleach as effective?

Please specify the duration of treatment with bleach and ethanol.

Effective Date: 9/25/2025

Project Expiration: 9/11/2025

Votes:

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

d. Review of AMEND202500095 Continuing review for 461982

PI:	Scott Laughlin
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under:	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

i. In Section: Protocol Team Members

Item 1. Please indicate who will be involved in the procedures.

ii. In Section: Exposure Assessment and Protective Equipment

Item 4. According to EHS records, the BSC in the indicated room is type A2, not A1. The certification date also doesn't match our records. Please correct.

iii. In Section: Waste Management

Item 1. Please indicate how long the EtOH will be applied to the contaminated area.

Item 2. Provide location of autoclave.

Effective Date: 8/22/2025

Project Expiration: 8/21/2026

Votes:

For:	8
Against:	0
Recused:	0
Absent:	0
Abstained:	0

7. Review Of Incidents

None

8. Review of Other Agenda Items

None

9. Inspection Results

None

10. Discussion Items/Readings (major and minor points of order)

None

11. Meeting Adjourned at 12:36PM